secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paysign, Inc. (PAYS)
CIK:        0001496443
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001683168-24-005176
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Paysign Q2 2024 revenue up 29.8% to $14.33M; raises full-year guidance
----------------------------------------------------------------------

- Net income of $697K ($0.01 diluted EPS) vs net loss of $104K in Q2 2023.
- Adjusted EBITDA $2.24M, up 95.8% YoY; plasma revenue +12.6%, pharma patient affordability revenue +266.8%.
- Added 8 net new plasma centers (477 total) and 8 net new patient affordability programs (61 total) in Q2.
- FY 2024 revenue guidance raised to $56.5-$58.5M; adjusted EBITDA guided $9.0-$10.0M (15-17% of revenue).
- Exited quarter with $31.29M unrestricted cash and zero debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496443/000168316824005176/0001683168-24-005176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496443/000168316824005176/paysign_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer